COVID-19 pandemic is an emergent cardiovascular risk factor and a major cause of mortality worldwide. Thromboembolism is highly suspected as a leading cause of death in these patients through vascular inflammation caused by SARS COV2. Until now there is no real treatment of COVID-19 and many proposed drugs are under clinical trials. Considering the high incidence of thromboembolic events in critically ill patients with COVID-19, prevention of this disorder should be essential in order to reduce mortality in these patients.
All Keywords
【저자키워드】 COVID-19, cardiovascular risk factors, Low and middle income countries, 【초록키워드】 Treatment, Mortality, COVID-19 pandemic, clinical trials, drug, cardiovascular risk, Patient, death, incidence, patients, Critically ill patient, disorder, vascular inflammation, Thromboembolic event, reduce mortality, caused, with COVID-19, 【제목키워드】 Patient, cardiovascular risk factor,
【저자키워드】 COVID-19, cardiovascular risk factors, Low and middle income countries, 【초록키워드】 Treatment, Mortality, COVID-19 pandemic, clinical trials, drug, cardiovascular risk, Patient, death, incidence, patients, Critically ill patient, disorder, vascular inflammation, Thromboembolic event, reduce mortality, caused, with COVID-19, 【제목키워드】 Patient, cardiovascular risk factor,